Vimarsana
Biggest News Aggregation in the World

Page 9 - Berkeley Lights Platform News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Berkeley Lights Platform. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Berkeley Lights Platform Today - Breaking & Trending Today

Berkeley Lights Announces CFO Transition and C-Level Additions - Vimarsana News

Berkeley Lights Announces CFO Transition and C-Level Additions

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Berkeley Lights Announces CFO Transition and C-Level Additions Berkeley Lights, IncFebruary 4, 2021 GMT Kurt Wood appointed CFO; Industry Veterans Pete Leddy, as CHRO, and Mimi Healy, as CPO, join Berkeley Lights Company to Report Fourth Quarter and Year-End 2020 Financial Results on February 25, 2021 EMERYVILLE, Calif., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Berkeley Lights, Inc. (Nasdaq: BLI), a leader in Digital Cell Biology, announced today the following organizational updates: Kurt Wood, currently t...

Source: apnews.com
Berkeley Lights, Inc: Berkeley Lights Launches Opto Plasma B Discovery 4.0 to Accelerate Therapeutic Antibody Discovery Against Difficult Targets - Vimarsana News

Berkeley Lights, Inc: Berkeley Lights Launches Opto Plasma B Discovery 4.0 to Accelerate Therapeutic Antibody Discovery Against Difficult Targets

(2) EMERYVILLE, Calif., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Berkeley Lights, Inc. (Nasdaq: BLI), a leader in Digital Cell Biology, today announced the Opto Plasma B Discovery 4.0 workflow. Opto Plasma B Discovery 4.0 is the industry's premier antibody discovery workflow by advancing from B cells to lead molecules in just 1 week. This workflow enables our customers to: Sample 4x more of the relevant biodiversity, screening up to 100,000 cells Functionally test with highly sensitive cell-based assays Recover not only sequences, but also re-expressed molecules without requiring costly gene synth...